Navigation Links
AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting

e attained an overall 52% CBR which compares favorably with the activity of mTOR inhibitors; - Low dose perifosine (daily and weekly) achieved the same CBR as high dose, including four partial responses; - Toxicities were mainly gastrointestinal and/or fatigue. Low dose perifosine led to substantially less toxicity and decreased early withdrawal from therapy compared to high dose perifosine.

A multi-center Phase 2 trial of low-dose perifosine in sarcomas that generally do not respond to chemotherapy, including chondrosarcoma and myxoid chondrosarcoma, is currently underway through the Sarcoma Alliance for Research through Collaboration (SARC) network.

About Perifosine (KRX-0401)

Perifosine is a novel, first-in-class, oral anti-cancer agent that modulates several key signal transduction pathways, including Akt, MAPK, and JNK that have been shown to be critical for the survival of cancer cells. Perifosine has demonstrated single agent anti-tumor activity in Phase 1 and Phase 2 studies and is currently being studied as a single agent and in combination with several forms of anti-cancer treatments for various forms of cancer. Perifosine (KRX-0401) is licensed to Keryx Biopharmaceuticals in the United States, Canada and Mexico.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aeternazentaris.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes", "anticip
'"/>




Page: 1 2 3 4

Related medicine technology :

1. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
2. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. GenoLogics Announces Bioinformatics Partnership with Illumina
9. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
10. Inovio Biomedicals Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials
11. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
Post Your Comments:
(Date:1/23/2015)... , Jan. 23, 2015  Immune Therapeutics, Inc. today announced the ... the compounding, packaging and distributing of its naltrexone tablets.  The ... United States . KRS Global is ... tablets in various strengths for individual patients in response to ...
(Date:1/23/2015)... 2015  iMD Companies, Inc. (ICBU) has repositioned itself as a ... grab a foothold in the hydroponic, hemp and medical marijuana ... presence in the sector, and recently partnering with the Chippewa ... and medical marijuana, iMD is committing to bring its vision ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... Directors has approved a share repurchase program. The open-ended ... million of Mallinckrodt plc ordinary shares. ... remain top priorities as we continue to pursue a ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: AMPE) today announced the ... of diabetic macular edema, an early stage of diabetic retinopathy. Diabetic macular ... , , , ... a formal agreement with St Michael ,s Hospital, Toronto, Canada ...
... N.J. , July 21 Actavis Group, the international ... the U.S. Food & Drug Administration to market Bupropion HCl Extended-Release ... immediately.   , , ... Bupropion HCl SR Tablets, the generic equivalent of Wellbutrin® SR by ...
Cached Medicine Technology:Ampio Pharmaceuticals Announces Initiation of Phase II Clinical Trial of Optina™ 2Actavis Receives Approval of Bupropion HCl SR 100mg and 200mg in the U.S. 2
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader ... designers are thrilled to have it lead the wedding dress ... collection of prom dresses for the global market. , “The ... vision and he focuses on continuing the goal of operational ...
(Date:1/22/2015)... 2015 Angelweddingdress is a famous wedding dress ... customers to follow it on Facebook, Twitter, and Pinterest. The ... gift. Angelweddingdress draws a lottery every week. , Moreover, the ... 28, 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, ... dresses. View website of AngelWeddingDress.com to find ... wedding dresses online for a bridal party. AngelWeddingDress offers ... for them. Its maternity wedding dresses are specially designed ...
(Date:1/22/2015)... 22, 2015 Juvent Sports ( http://www.juventsports.com ... 2015 PGA Merchandise Show to bestow a Juvent Sports ... amateur golfer, Arlene McKitrick. The award commemorated and congratulated ... tournament win. She won her first amateur tournament in ...
(Date:1/22/2015)... January 22, 2015 Thousand of GranuFlo ... Care recalled its GranuFlo and NaturaLyte dialysis concentrates continue ... in U.S. District Court, District of Massachusetts, Bernstein Liebhard ... the Court has remanded a case filed by the ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... REMS consulting, design and implementation -PRINCETON, N.J., March 31 ... ) experts will present key insights on risk management ... 5th Annual CBI Bio/Pharmaceutical Drug Safety Forum from March ... Covance,s vice president of medical affairs for periapproval services ...
... March 31 The following is a statement from Jeff ... recall of pistachios is the latest reminder of how vulnerable ... is not adequately set up to respond to many modern ... is out-of-date, under-resourced, and understaffed. It is encouraging that this ...
... Together To Share and Learn From Each OtherMOUNTAIN VIEW, Calif., ... industry leader in personal genetics, announced today that it has ... with the goal of connecting women together and ... enjoyable pregnancies for all women.Moms of all ages are welcome ...
... 30% of Supplements Selected for Testing and Finds Most Children,s Multivitamins ... ... (PRWEB) March 31, 2009 -- Over 30% of multivitamins recently selected ... less ingredient than claimed or were contaminated with lead. In addition, ...
... Repligen Corporation (Nasdaq: RGEN ) announced today that ... uridine in the treatment of patients with bipolar disorder from ... of patients with bipolar disorder is currently the subject of ... in force until 2025 prior to any regulatory extensions. ...
... HIMSS09 Conference , April 4 - 8 in ChicagoCHICAGO, March ... America,s leading Workforce Management consulting firm, ... a practice dedicated to the Workforce Management (WFM) needs of ... at HIMSS09 , the Healthcare Information and ...
Cached Medicine News:Health News:Covance Experts to Present Key Insights on Risk Management at Bio/Pharmaceutical Drug Safety Forum 2Health News:Covance Experts to Present Key Insights on Risk Management at Bio/Pharmaceutical Drug Safety Forum 3Health News:Trust for America's Health on the Recall of Certain Pistachios and the U.S. Food Safety System 2Health News:23andMe Launches Free Online Community for Moms and Moms-to-Be 2Health News:23andMe Launches Free Online Community for Moms and Moms-to-Be 3Health News:ConsumerLab.com Warns of Problems with Mulitivitamins and Vitamin Water 2Health News:ConsumerLab.com Warns of Problems with Mulitivitamins and Vitamin Water 3Health News:ConsumerLab.com Warns of Problems with Mulitivitamins and Vitamin Water 4Health News:ConsumerLab.com Warns of Problems with Mulitivitamins and Vitamin Water 5Health News:Repligen Licenses Patent Rights for Treatment of Bipolar Disorder 2Health News:Repligen Licenses Patent Rights for Treatment of Bipolar Disorder 3Health News:Repligen Licenses Patent Rights for Treatment of Bipolar Disorder 4Health News:Axsium Group Launches Workforce Management Practice for Healthcare Industry 2Health News:Axsium Group Launches Workforce Management Practice for Healthcare Industry 3
... The Bile Reflux Analysis for POLYGRAM NET® ... Application. This add-on allows medical professionals to upload ... ambulatory bile reflux recorder. The primary difference is ... absorbance of a certain wavelength of light corresponding ...
Symbia T6, a True Point SPECT·CT system, combines a dual-detector variable angle gamma camera with a six slice CT scanner for advanced oncology, neurology, and cardiology applications....
... ACOM.Net is a high-efficiency network for ... data security on an expandable platform., If ... and archive DICOM 3 images in real-time ... different workstations without loss of speed, Connect ...
... the AXIOM Artis dBC Magnetic Navigation ... navigation system equipped with digital flat ... is uniquely capable of improving the ... to facilitate increased efficiency and productivity ...
Medicine Products: